Related references
Note: Only part of the references are listed.Effects of Low-Dose Spironolactone Combined with Metformin or Either Drug Alone on Insulin Resistance in Patients with Polycystic Ovary Syndrome: A Pilot Study
Tao Long et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2022)
Metabolic profile of women with PCOS in Brazil: a systematic review and meta-analysis
Poli Mara Spritzer et al.
DIABETOLOGY & METABOLIC SYNDROME (2021)
Health related quality of life and psychological parameters in different polycystic ovary syndrome phenotypes: a comparative cross-sectional study
Bahadori Fatemeh et al.
JOURNAL OF OVARIAN RESEARCH (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer
Jose A. Carlos-Escalante et al.
FRONTIERS IN ONCOLOGY (2021)
Association between biochemical hyperandrogenism parameters and modified Ferriman-Gallwey score in patients with hirsutism in Basrah (Southern Iraq)
Rudha Naser Hussein et al.
POSTEPY DERMATOLOGII I ALERGOLOGII (2021)
Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS
Mohd Ashraf Ganie et al.
GYNECOLOGICAL ENDOCRINOLOGY (2020)
Comparative efficacy of statins, metformin, spironolactone and combined oral contraceptives in reducing testosterone levels in women with polycystic ovary syndrome: a network meta-analysis of randomized clinical trials
Hussain H. Almalki et al.
BMC WOMENS HEALTH (2020)
Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data
Megan Shuey et al.
BMJ OPEN (2020)
Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
Tetsuro Tsujimoto et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhe Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Safety of 5-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
Raquel N. Rozner et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society* Clinical Practice Guideline
Kathryn A. Martin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial
Macarena Alpanes et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review
Alison M. Layton et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome
Halit Diri et al.
GYNECOLOGICAL ENDOCRINOLOGY (2016)
Spironolactone in the treatment of polycystic ovary syndrome
Decio Armanini et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials
Jie V. Zhao et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2016)
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial
Morris J. Brown et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations
M. Geoffrey Hayes et al.
NATURE COMMUNICATIONS (2015)
Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: A randomized controlled trial
Supatra Leelaphiwat et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2015)
Polycystic Ovary Syndrome: Perceptions and Attitudes of Women and Primary Health Care Physicians on Features of PCOS and Renaming the Syndrome
Helena Teede et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone
A. Mazza et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2014)
Improved Efficacy of Low-Dose Spironolactone and Metformin Combination Than Either Drug Alone in the Management of Women With Polycystic Ovary Syndrome (PCOS): A Six-Month, Open-Label Randomized Study
Mohd Ashraf Ganie et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Cellular and molecular mechanisms of metformin: an overview
Benoit Viollet et al.
CLINICAL SCIENCE (2012)
Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: Randomized comparison of three regimens
Kiymet Handan Kelekci et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2012)
Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome
Katica Bajuk Studen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Managing Polycystic Ovary Syndrome What Our Patients Are Telling Us
Joan Crete et al.
JOURNAL OF HOLISTIC NURSING (2011)
Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome
Levent Kebapcilar et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2010)
Metabolic features of the reproductive phenotypes of polycystic ovary syndrome
Lisa Moran et al.
HUMAN REPRODUCTION UPDATE (2009)
Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline
Wylie C. Hembree et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne
Julie Brown et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2009)
Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism:: A randomised controlled study
Feridun Karakurt et al.
ADVANCES IN THERAPY (2008)
Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome
Caroline Meyer et al.
DIABETES CARE (2007)
Guidelines on the management of ascites in cirrhosis
K. P. Moore et al.
GUT (2006)
Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study
MM Inal et al.
FERTILITY AND STERILITY (2005)
Spironolactone for hirsutism in polycystic ovary syndrome
NA Christy et al.
ANNALS OF PHARMACOTHERAPY (2005)
Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile
E Zuhan et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2005)
A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism
F Kelestimur et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: An open-labeled study
MA Ganie et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism
F Lumachi et al.
FERTILITY AND STERILITY (2003)
Spironolactone as a single agent for long-term therapy of hirsute patients
PM Spritzer et al.
CLINICAL ENDOCRINOLOGY (2000)
Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial
P Moghetti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Share Paper
